Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M607275200 on November 13, 2006

J. Biol. Chem., Vol. 282, Issue 1, 240-248, January 5, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/1/240    most recent
M607275200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nemetski, S. M.
Right arrow Articles by Gardner, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nemetski, S. M.
Right arrow Articles by Gardner, L. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Hypoxic Regulation of Id-1 and Activation of the Unfolded Protein Response Are Aberrant in Neuroblastoma*

S. Maureen Nemetski and Lawrence B. Gardner1

From the Department of Medicine, Pharmacology and the New York University Cancer Institute, The New York University School of Medicine, New York City, New York 10016

Received for publication, August 1, 2006 , and in revised form, October 25, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The Id proteins play an important role in proliferation, differentiation and tumorigenesis. Many tumors are hypoxic, but it is unknown if expression of Id proteins is regulated in hypoxic cells. Here we show that Id-1 is down-regulated in multiple primary, immortalized, and neoplastic hypoxic cell lines, and the transcriptional repressor ATF-3 is both necessary and sufficient for this hypoxia-induced repression of Id-1. Hypoxic up-regulation of ATF-3 is due in part to activation of the unfolded protein response, a cellular stress response. Remarkably, we observe that the unfolded protein response is de-regulated in all neuroblastoma cell lines tested. Indeed, in the absence of ATF-3 the hypoxia-induced transcription factor HIF-1 up-regulates Id-1 in hypoxic neuroblastoma cells. Hypoxic neuroblastoma cells diminish expression of some neuronal differentiation markers, and forced expression of ATF-3 in hypoxic neuroblastoma cells represses Id-1 and prevents the loss of these markers. The divergent regulation of Id proteins in distinct hypoxic cells may explain some of the varied effects hypoxia has on cellular differentiation and proliferation.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Many tumors are profoundly hypoxic and multiple studies have demonstrated that hypoxic tumors have a poorer prognosis than non-hypoxic tumors. Although the full etiology of this observation is unclear, many of the phenotypes associated with hypoxic cells are due to the induction and suppression of gene expression (reviewed in Ref. 1). While the hypoxia-inducible transcription factor, HIF-1, is the best characterized inducer of gene transcription in hypoxic cells, it is clear that additional signaling pathways can both up-regulate and down-regulate gene expression in hypoxic cells (2, 3). In addition, HIF-1 targets differ dramatically in various cell types despite similar expression of HIF-1{alpha} (3–6) suggesting that HIF-1 transcriptional activity may be modulated by cell specific factors.

The existence of cell-specific factors may play a role in the marked phenotypic differences noted between different hypoxic cell lines and tumors. For example, most normal cells and many neoplastic cells undergo a growth arrest when hypoxic, whereas some stem cells and neoplastic cells continue to proliferate under hypoxic conditions (7, 8). Studies have also suggested that hemangioblasts, renal tubular cells, and embryonic stem cells all differentiate when hypoxic, while hypoxic adipocytes and hematopoietic stem cells are resistant to differentiation (9–12). Neuroblastoma cells, when rendered hypoxic, lose some neuronal markers, leading to the hypothesis that they undergo hypoxic "de-differentiation" to immature neural crest cells (13). Despite the probability that hypoxic regulation of proliferation and differentiation play an important role in the aggressiveness of hypoxic tumors, the mechanisms by which hypoxic cells regulate proliferation and differentiation have not been fully delineated.

The Id proteins play an important role in both proliferation and differentiation, although their regulation in hypoxic cells has not been well studied. Id proteins, consisting of Id-1, Id-2, Id-3, and Id-4, act as inhibitors of DNA binding and inhibitors of differentiation. These proteins contain helix-loop-helix (HLH)2 motifs, but unlike HLH transcription factors they do not contain DNA binding domains. Thus Id proteins can heterodimerize with HLH transcription factors, prevent these transcription factors from binding to DNA and transactivating genes, and act in a dominant negative fashion. Id proteins can heterodimerize with two classes of HLH transcription factors. Class I HLH transcription factors are ubiquitous and encompass the E2A transcription factor, which functions as a tumor suppressor and inhibits proliferation. Class II HLH transcription factors are tissue-specific and regulate genes necessary for nerve, muscle, and T cell development (reviewed in Ref. 14).

The importance of Id family members in cancer is supported by the fact that Id overexpression promotes immortalization (15), proliferation (16), and angiogenesis and neo-vascularization (17, 18). The ability of Id proteins to inhibit differentiation may play an important role in tumorigenesis, as loss of differentiation is a hallmark of cancer cells. The Id proteins play a particularly well documented role in the biology of neuroblastoma. Id family members are highly expressed in neuroblastoma, prevent pharmacological differentiation of neuroblastoma cells lines (19, 20), and may indicate a poor prognosis (16, 19).

Through a non-biased screen for transcription factors altered in hypoxic fibroblasts we determined that Id-1 expression is decreased in a variety of primary, immortalized, and neoplastic cells when they are rendered hypoxic. We therefore pursued the mechanism and significance of hypoxic Id-1 regulation and sought to determine whether hypoxic regulation of Id-1 is aberrant in some cancers.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines and Reagents—ATF-3–/– MEFs and Corresponding Wild-type MEFs were the kind gift of Twsonin Hai (21), ATF-4–/– MEFs (22) and PERK–/– MEFs (23), as well as their corresponding wild-type MEFs, were the generous gift of David Ron, and eukaryotic initiation factor 2 (eIF2{alpha}) S51A knock-in MEFs and corresponding wild-type MEFs were the gift of R. Kaufman (24). Neuroblastoma cell lines were obtained from ATCC. All cells were grown in DMEM, 10% FCS, except for MEFs, which were grown in DMEM, 10% FCS, NEAA, and beta-mercaptoethanol as described. Prior to experiments, all cells were washed in phosphate-buffered saline, transferred to DMEM with 1 gm/dl glucose, 10% FCS, 25 mM HEPES to buffer against acidosis. Cells were incubated at 37 °C degrees, in either 5% CO2, or in a Plas-Labs environmental chamber. Oxygen concentration in the chamber was maintained at <0.1% in chamber for all experiments as assessed by an Alpha Omega Oxygen Analyzer.

Retroviral Infection—RT-PCR was performed on normoxic (for Id-1) or hypoxic (for ATF-3) U2OS cells. C-terminal Flag tagged Id-1 was cloned in HindIII and XhoI sites of pLPC (gift from S. Lowe) using PCR primers upstream (US) 5'-GAAGCTTAGGTGGAATTGCCACCATGAAAGTCGCCAGTGGCAGC-3' (wild-type) or 5'-GGAAGCTTAGGTGGAATTGCCACCATGGAAGTCGCCAGTGGCAGC-3' ({Delta}2D) and downstream (DS) 5'-ATGCTCGAGCGTCACTTGTCATCGTCGTCCTTGTAGTCGCGACACAAGTGCGATCGTCCGCAGG-3'. ATF-3 was cloned into HindIII and BAMH1 sites using the primers US (5'-CGATCTAGAAAGCTTGCCACCATGATGCTTCAACACCCAGGCCAGGTCTCT-3') and DS (5'-GCGGATCCGTCGACTTAGCTCTGCAATGTTCCTT-3'). Retrovirus was obtained by co-transfecting 293GP cells (gift of Michele Pagano) with vesicular stomatitis virus glycoprotein and plasmid, and the supernatant was used to infect cells for 12 h x 3. Cells were then selected with 2 µg/ml puromycin. The HIF-1{alpha} shRNA sequence (AGAGGTGGATATGTCTGGG) and scramble sequence (GGGTCTGTATAGGTGGAGA) (25) were cloned into a LKO.1 lentivirus. Lentivirus was prepared by infecting 293T cells with the LKO.1 plasmid, {Delta}8.9CR2 plasmid, and vesicular stomatitis virus glycoprotein plasmids (3:1:4 ratio) and collecting the supernatant for 3 days post infection. SK-N-BE(2) cells were infected for 12 h x 3 and selected with puromycin.

Half-life—Immortalized MEFs infected with pLPC or pLPC-WT Id-1 retroviruses were rendered hypoxic for 16 h and then treated with cyclohexamide (50 µg/ml) for the described times.

Immunoblot—Cells were scraped in phosphate-buffered saline and re-suspended with lysis buffer containing protease inhibitors as described (23) and briefly sonicated. 20–40 µgof whole cell extract were electrophoresed and transferred to nitrocellulose. ATF-4 was detected in nuclear extracts prepared from cells treated as indicated in the figure legends. Antibodies against Id-1 (sc-488), ATF-3 (sc-188) eIF2{alpha} (sc 11386) and ATF-4 (sc-200) VEGF (sc-152) were obtained from Santa Cruz Biotechnology, HIF-1{alpha} from Novus Biologicals, and eIF2{alpha} phosphorylated S51 from Epitomics. Immunoblots were quantitated on a Bio-Rad GS800 Calibration Densitometer.

Gene Expression—RNA was isolated with TRIzol and cDNA made with 200 ng of total RNA using a Stratagene kit. 2% of the resulting cDNA was used for either real-time PCR with SybrGreen (Applied Biosystems) or semiquantitative RT-PCR with REDTaq ReadyMix (Sigma) according to the manufacturer's protocol. PCR protocols consisted of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s for 33 (semiquantitative) or 45 (real-time) cycles. Data for real-time PCR was normalized to 18 S RNA. Primers for semiquantitative PCR include murine Id-1 (5'-CCAGTGGCAGTGCCGCAGCCGCTGCAGGC and 3'-GGCTGGAGTCCATCTGGTCCCTCAGTGC) and murine ATF-3 (5'-GGTGGAATTCGAGCGAAGACTGGAGCAAAA and 3'-AACCTCGAGGTGGGGTGGAAAAGGAGGA. 3'-Primers for real-time PCR include: 18S, 5'-GGACACGGACAGGATTGACA-3' and 5'ACCCACGGAATCGAGAAAGA-3'; murine Id-1, 5'-GAGTCTGAAGTCGGGACCAC-3' and 5'-GATCGTCGGCTGGAACAC-3'; murine ATF-3, 5'-TGCCAAGTGTCGAAACAAGA-3' and 5'-CCTTCAGCTCAGCATTCACA-3'; human Id-1, 5'-TGAAACACTGGCGAGGA-3' and 5'-GACCCCCTAAAGTCTCTGGTGA-3'; NSE, 5'-CCCCAATATCCTGGAGAACA-3' and 5'-CAACATCCATGCCAATAACG-3' NF-L, 5'-TACACCAGCCATGTCCAAGA-3' and 5'-TCTTCAGCTGCCTCCTCTTC-3'; NPY, 5'-CTCGCCCGACAGCATAGTA-3' and 5'-CCCCAGTCGCTTGTTACCT-3'; GAP43, 5'-AGAGCAGCCAAGCTGAAGAG--3' and 5'-TCAGGCATGTTCTTGGTCAG-3'; ATF-4, 5'-GACGGAGCGCTTTCCTCTT-3' and 5'-TCCACAAAATGGACGCTCAC-3'; human ATF-3, 5'-GCCATTGGAGAGCTGTCTTC-3' and 5'-GGGCCATCTGGAACATAAGA-3'; CHOP, 5'-CAGAACCAGCAGAGGTCACA-3' and 5'-AGCTGTGCCACTTTCCTTTC; Sox9, 5'-AGTACCCGCACTTGCACAAC and 3'-GCTTCTCGCTCTCGTTCAGA.

Luciferase Promoter Assay—Id-1 promoter/luciferase constructs (26), the kind gift of Frances Ventura, were transfected into human kidney epithelial cells using FuGENE 6. After 24 h or recovery cells were rendered either hypoxic or maintained as normoxic for an additional 16 h, at which time luciferase activity was determined with the Promega luciferase assay system according to the manufacturer's protocol.

Electromobility Shift Assay (EMSA)—EMSA were performed as described (8). Oligonucleotides for the Id-1 promoter were 5'-AATGGGTGACGTCACAGGCCTG-3' and mutant 5'-GGAATGGGAAACGTCACAGGCCTG-3'.

XBP Splicing Assay—Cells were rendered hypoxic or treated with tunicamycin, RNA was isolated, and PCR was performed with the primers 5'-AAACAGAGTAGCAGCTCAGACTGC-3' and 5'-TCCTTCTGGGTAGACCTCTGGGAG-3'. RT-PCR was then performed with SuperScript One-Step RT-PCR with Platinum Taq (Invitrogen) according to the manufacturer's protocol.


Figure 1
View larger version (28K):
[in this window]
[in a new window]

  		FIGURE 1.
Id-1 is down-regulated in hypoxic cells by ATF-3. A, a variety of cell lines were rendered hypoxic for 16 h, and Id-1 protein levels were determined by anti Id-1 immunoblot. Coomassie Blue staining of duplicate gels (coom.) serves as a loading control. B, MEF cells were stably infected with vectors expressing either Id-1 or empty vector controls, and cell lysates were collected after the indicated periods of cycloheximide (CHX) treatment in normoxic (N) or after cells had been rendered hypoxic (Hy) for 16 h. Id-1 expression was determined by anti-Id-1 or anti-FLAG immunoblot for the endogenous and exogenous proteins respectively. Densitometry of bands from three to four independent experiments was determined, and the average ± S.E. are displayed graphically below the immunoblots. C, Id-1 RNA is diminished in 16 h hypoxic wild-type MEFs but not in hypoxic ATF-3 knock-out MEFs as determined by semiquantitative RT-PCR (above, with actin RT-PCR serving as a control for imput RNA integrity) and by quantitative real-time PCR (D). *, p = 0.03 by two-sided Student's t-test. E, human kidney epithelial cells were transfected with Id-1 promoter/luciferase reporters (above) as detailed under "Experimental Procedures." After 16 h luciferase activity was assessed; data reflect hypoxic/normoxic luciferase activity of the Id-1 promoter and the Id-1 promoter with a mutated ATF motif, normalized to empty pGL2 vector. F and G, immunoblots reveal that ATF-3 is induced in a variety of hypoxic (Hy) primary, immortalized, and transformed cell lines including HaCAT (C) and MEF and U2OS cells (D) when compared with normoxic (N) cells. Coomassie (coom.) serves as the loading control.

 

   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Id-1 Is Down-regulated in Hypoxic Cells via Transcriptional Repression Mediated by ATF-3—During the course of an unbiased screen to identify transcription factors with altered activity in hypoxic cells, we determined that Id-1 protein expression is diminished in a variety of hypoxic primary, immortalized, and transformed cell lines (Fig. 1A and data not shown). Because down-regulation of Id-1 might explain in part why some hypoxic cells undergo a growth arrest and/or differentiate, we pursued the mechanism for Id-1 down-regulation in hypoxic cells.

Previous studies have demonstrated that Id-1 expression can be regulated at both the post-translational and transcriptional level (27, 28). To delineate the mechanism for decreased Id-1 expression in hypoxic cells we first investigated potential post-translational regulation of Id-1 in hypoxic cells. Mouse embryo fibroblasts (MEFs) stably expressing tagged Id-1 from a retroviral construct were treated with cycloheximide, and lysates were collected at regular intervals and subjected to immunoblot to assess stability of the Id-1 protein. There was no significant difference in the half-life of endogenous versus exogenous Id-1 proteins in normoxic cells (Fig. 1B) demonstrating that overexpression of exogenous Id-1 does not affect the kinetics of its degradation. In contrast to endogenous Id-1 protein expression, exogenous Id-1 expression (where Id-1 transcription is mediated by a retroviral LTR promoter instead of the native Id-1 promoter) was not repressed in hypoxic cells (Fig. 1B) suggesting that endogenous Id-1 is regulated at the transcriptional level in hypoxic cells. In addition, the half-life of exogenous Id-1 protein was not significantly altered in hypoxic cells compared with normoxic cells (Fig. 1B, with the average of three independent experiments ± S.E. shown graphically below). Together, these data demonstrate that Id-1 translation and degradation are not altered in hypoxic cells and suggest Id-1 may be transcriptionally repressed in hypoxic cells.

We next examined directly whether transcriptional repression of the Id-1 promoter occurs in hypoxic cells. MEFs rendered hypoxic demonstrated a rapid decrease in Id-1 mRNA as determined by semiquantitative PCR and quantitative PCR (Fig. 1, C and D). To determine whether the decrease of Id-1 mRNA in hypoxic cells is due to direct transcriptional repression of the Id-1 promoter or a result of decrease in Id-1 mRNA stability, we transfected a luciferase construct containing ~1.4 kilobases of the Id-1 proximal promoter (26) into human kidney epithelial cells and rendered these cells hypoxic for 16 h. When compared with transfected normoxic cells, there was a significant repression of the Id-1 promoter-driven reporter in hypoxic cells (Fig. 1E). In total, these data demonstrate that transcription of Id-1 is repressed in hypoxic cells.

We then pursued the mechanism by which Id-1 is transcriptionally repressed in hypoxic cells. TGFbeta-1 has recently been reported to down-regulate Id-1 mRNA in immortalized HaCAT (human keratinocytes) cells via an ATF-3 binding site in the Id-1 proximal promoter (27). ATF-3 is a member of a family of stress-induced transcription factors. Whereas other ATF family members are transcriptional activators, ATF-3 has been reported to serve either as a transcriptional activator or repressor, depending on the cellular context (reviewed in Ref. 29). We found that HaCAT cells also down-regulate Id-1 and up-regulate ATF-3 when rendered hypoxic (Fig. 1F), as do a number of other normal and transformed cell lines (Fig. 1G and data not shown). Quantitative RT-PCR confirmed a greater than 5-fold reduction of Id-1 mRNA and 5-fold up-regulation of ATF-3 mRNA in wild-type MEFs by 4 h (Fig. 1D). Importantly Id-1 RNA is not repressed in hypoxic ATF-3–/– MEFs, and in fact a modest but significant up-regulation of Id-1 mRNA was noted in hypoxic ATF-3–/– MEFs at 8 h (Fig. 1D). Similarly, Id-1 protein expression was only mildly repressed in hypoxic ATF-3–/– MEFs as compared with wild-type MEFs (data not shown). In contrast to the native Id-1 proximal promoter, an Id-1 promoter construct with a mutated ATF site was not repressed in hypoxic cells (Fig. 1E). Thus hypoxia-induced ATF-3 is necessary for the hypoxic repression of Id-1.

ATF-3 Is Induced in Hypoxic Cells in Part by the Unfolded Protein Response—Since our data demonstrate that ATF-3 is necessary for the hypoxia-induced down-regulation of Id-1, we next focused on the mechanism of the hypoxic up-regulation of ATF-3. ATF-3 is induced by cytokines and a variety of stresses, including UV irradiation, DNA damage, and ischemia/reperfusion (reviewed in Ref. 29). The transcriptional activator ATF-4 has also been implicated in the up-regulation of ATF-3 (23). ATF-4, in turn, can be induced by multiple stresses including protein misfolding in the endoplasmic reticulum and subsequent activation of the unfolded protein response (UPR). The UPR is a stress response pathway in which a global inhibition of protein synthesis leads to increased expression of stress response genes which serve to adapt cells to this increased stress. One of the central mechanisms in this stress response is the phosphorylation of the alpha subunit of eIF2{alpha} on serine 51 by the UPR-activated PERK kinase (30). Phosphorylation of eIF2{alpha} by the PERK kinase leads to both general translational inhibition and a paradoxical increased translation of a small subset of proteins, including ATF-4. Because both activation of the UPR and up-regulation of ATF-4 have recently been demonstrated to occur in hypoxic cells (31–34), we explored whether hypoxic activation of the UPR and up-regulation of ATF-4 leads to the hypoxic up-regulation of ATF-3 and subsequent repression of Id-1.

When compared with wild-type MEFs, ATF-3 induction was diminished in hypoxic ATF-4–/– MEFs (Fig. 2A) and PERK-MEFs (Fig. 2B). In hypoxic MEFs in which the endogenous eIF2{alpha} gene has been genetically replaced by an eIF2{alpha} allele, which cannot be phosphorylated (S51A) (and thus the PERK dependent branch of the UPR cannot be activated) (24), ATF-4 expression was entirely blunted, and both ATF-3 induction and Id-1 repression were diminished 3-fold (Fig. 2C, quantitation in right panel). Consistent with hypoxic activation of the unfolded protein response, ATF-4 mRNA was not increased in hypoxic cells suggesting that the increased expression of ATF-4 is due to translational regulation (Fig. 2D). Also consistent with activation of the UPR pathway, ATF-3 and an additional ATF-4 target CHOP were induced at the mRNA level in hypoxic cells (Fig. 2D). Thus we conclude that in hypoxic cells PERK is activated, leading to eIF2{alpha} phosphorylation and ATF-4 generation, which in turn leads to ATF-3 induction and Id-1 repression (Fig. 2E). Because some detectable ATF-3 is generated in hypoxic PERK–/–, ATF-4–/–, and eIF2{alpha} S51A cells, there are additional mechanisms for the hypoxic induction of ATF-3 (dashed lines in Fig. 2E). Other signaling pathways implicated in the induction of ATF-3 include the p38/MAP kinase signaling pathway (reviewed in Ref. 29); however, we did not note either activation of p38 in hypoxic MEFs or alteration of ATF-3 expression with p38 inhibition in hypoxic MEFs (data not shown). We have, however, noted significant stabilization of ATF-3 mRNA in hypoxic cells.3 What role this prolongation of ATF-3 mRNA half-life has in explaining UPR independent mechanisms for ATF-3 induction and Id-1 repression in hypoxic cells remains to be determined.

The Induction of ATF-3 and Repression of Id-1 Does Not Occur in Neuroblastoma Cell Lines—Because Id-1 is highly expressed in many cancers and appears to play an important role in tumorigenesis, we hypothesized that hypoxia-induced down-regulation of Id-1 might be aberrant in some neoplastic cells. Although we observed that Id-1 protein is down-regulated in over 10 cell lines, including several neural and astrocytoma cell lines, when rendered hypoxic (data not shown), previous literature suggested that Id-1 and Id-2 mRNA are actually induced in several hypoxic neuroblastoma cell lines at short time points (19). Under our conditions, we also observed that indeed Id-1 protein was induced after 16 h of hypoxia in multiple neuroblastoma cell lines (SK-N-BE(2), SH-SY5Y, and SK-N-SH) (Fig. 3A). To determine why the UPR does not down-regulate Id-1 in hypoxic neuroblastoma cells as it does in the many other cell lines we studied, we assessed the activation of the UPR in neuroblastoma. Remarkably, ATF-3 was minimally induced in hypoxic neuroblastoma cells at the protein or RNA level (Fig. 3A). In contrast to U2OS cells, ATF-3 was also not expressed in neuroblastoma cells with other ER stresses, such as tunicamycin, thapsigargin (data not shown), or the calcium ionophore A23187 [GenBank] (35) (Fig. 3B).

ATF-4 was also not induced in neuroblastoma cells rendered hypoxic for 4, 8, or 16 h (data not shown and Fig. 3C). Induction of CHOP, a pro-apoptotic protein that is another ATF-4 target, was also dependent on eIF2{alpha} phosphorylation and was also not observed in hypoxic neuroblastoma cells (Fig. 3C). Since the central component of the UPR is eIF2{alpha} phosphorylation, we examined the phosphorylation status of eIF2{alpha} in hypoxic neuroblastoma cells. There was no difference in total amount of eIF2{alpha} in neuroblastoma cells when rendered hypoxic (Fig. 3C). However, we noted that as opposed to the marked phosphorylation of eIF2{alpha} in hypoxic MEFs, there was a paradoxical high basal level of eIF2{alpha} phosphorylation in normoxic neuroblastoma cells, which did not markedly increase when these cells were rendered hypoxic (Fig. 3C).


Figure 2
View larger version (36K):
[in this window]
[in a new window]

  		FIGURE 2.
ATF-3 is induced in hypoxic cells via the unfolded protein response. ATF4–/– (A), PERK–/– MEFs (B), and eIF2a S51A knock-in MEFs (lacking phosphorylatable eIF2a) (C) along with their wild-type counterparts were rendered hypoxic for 16 h, and expression of ATF-3, ATF-4, and Id-1 was determined by immunoblots. Coomassie Blue (coom.) staining serves as a loading control. ATF-3 induction and Id-1 repression in hypoxic (Hy) and normoxic (N) eIF2a wild-type MEFs and eIF2a S51A MEFs from four independent experiments were determined by immunoblot and quantitated by densitometry. Average ± S.E. of the level in hypoxia divided by the level in normoxia are displayed graphically. *, p = 0.05; **, p = 0.005 by two-sided Student's t-test. D, HeLa and U2OS cells were rendered hypoxic for 8 h, and the mRNA levels of ATF-4, ATF-3, and CHOP were determined by real-time PCR with specific primers and compared with mRNA expression levels in normoxic cells. The results were normalized to 18 S RNA expression, which did not vary in hypoxic cells. E, a model of ATF-3 induction and Id-1 repression in hypoxic cells, as determined from these studies and others (23). Interrupted lines demonstrate additional mechanisms not yet identified.

 
The lack of ATF-4 up-regulation and the induction of ATF-4 targets in hypoxic neuroblastoma cells could be due to a specific defect in the PERK-eIF2{alpha} axis or alternatively due to a general reduction in ER stress (i.e. misfolded proteins) either generated or sensed in hypoxic neuroblastoma cells. To evaluate these potential explanations, we explored the activation of a PERK-independent branch of the UPR in neuroblastoma cells, splicing of the mRNA for the transcription factor XBP1, which is mediated by IRE1 endonuclease activation by ER stress (36). When neuroblastoma cells were either rendered hypoxic or treated with a chemical inducer of ER stress, there was significant splicing of XBP1, comparable with the splicing seen in HaCAT cells or the glioblastoma cell line LN229 (Fig. 3D), demonstrating that ER stress is generated in neuroblastoma cells, and the UPR defect in these cells is specifically in the PERK-eIF2{alpha}-dependent branch of the UPR.

Finally, to determine whether the lack of UPR activation (and subsequent lack of ATF-3 induction) in hypoxic neuroblastoma cells was necessary for Id-1 induction, we created a retrovirus for exogenous expression of ATF-3. As seen previously, ATF-3 was up-regulated and Id-1 was down-regulated in hypoxic HaCAT cells but not in hypoxic SK-N-BE(2) cells (Fig. 3E). Importantly, when ATF-3 was constitutively expressed in neuroblastoma cells, Id-1 induction was prevented when cells were rendered hypoxic (Fig. 3E). These data demonstrate a causal role of ATF-3 induction and the UPR in the hypoxic repression of Id-1.

HIF-1 Transactivates Id-1 in the Absence of the UPR—Although the lack of ATF-3 up-regulation in hypoxic neuroblastoma cells explains why Id-1 expression is not repressed in these cells, we noted an actual induction of Id-1 in hypoxic neuroblastoma cells (Fig. 3, A and E). A similar, although more modest, induction of Id-1 was noted in hypoxic ATF-3–/– MEFS (Fig. 1F). Because Id-2 has been demonstrated to be a HIF-1 target in neuroblastoma cells (37), we sought to determine whether Id-1 is also a HIF-1 target. We constructed a lentivirus expressing a shRNA directed against HIF-1{alpha}. Expression of this shRNA efficiently knocked down HIF-1{alpha} expression in hypoxic SK-N-BE(2) cells as compared with a scrambled sequence (Fig. 4A). In the absence of HIF-1a, hypoxic neuroblastoma cells did not up-regulate Id-1 or the HIF-1 target VEGF (Fig. 4A). In addition, knock-down of HIF-1{alpha}, which resulted in a reduction of hypoxic mRNA up-regulation of the HIF-1 targets enolase and lactate dehydrogenase, also resulted in a 10-fold reduction in Id-1 mRNA induction in neuroblastoma cells (Fig. 4B). Therefore, hypoxic cells may either repress Id-1 though the generation of ATF-3, or up-regulate Id-1 through HIF-1, as seen in neuroblastoma cells.


Figure 3
View larger version (64K):
[in this window]
[in a new window]

  		FIGURE 3.
ATF-3 is not induced, and Id-1 is induced, in hypoxic neuroblastoma cell lines. A, cells were rendered hypoxic (Hy) or maintained as normoxic (N) for 16 h, and protein (top half) and RNA (for RT-PCR, lower two panels) were harvested in an osteosarcoma cell line (U2OS) and three neuroblastoma cell lines. Coomassie Blue (coom.) serves as a loading control for the immunoblot, and actin serves as an imput RNA integrity control for the RT-PCR. B, a neuroblastoma cell line (SH-SY5Y) and U2OS cells were treated for 6 h with several stresses known to induce the UPR, including tunicamycin at 2.5 µg/ml and the calcium ionophore A23187 at 10 µM, and ATF-3 expression was determined by immunoblot. Induction of HIF-1{alpha} expression confirms exposure to hypoxic conditions. C, wild-type MEFs, eIF2{alpha} S51A knock-in cells, and two neuroblastoma cell lines were rendered hypoxic for 4 h. ATF-4, CHOP, total eIF2{alpha}, and phosphorylated eIF2{alpha} levels were determined by immunoblot, n.b. irrelevant lanes have been excised, and thus this gel is a composite. D, epithelial (HaCAT), astrocytoma (LN229), and two neuroblastoma cell lines were rendered hypoxic for 9 or 16 h or treated with 2.5 µg/ml tunicamycin for 9 h. RNA was isolated and PCR performed for XBP as described under "Experimental Procedures." E, HaCAT cells and SK-N-BE(2) cells either infected with a control retrovirus or a retrovirus expressing ATF-3 were rendered hypoxic for 16 h, and ATF-3 and Id-1 protein levels were assessed by immunoblot.

 
Since these data demonstrate that Id-1 is regulated by HIF-1 in hypoxic neuroblastoma cells, we sought to determine whether Id-1 is a direct HIF-1 target. The ATF (CREB) binding site responsible for TGFbeta-induced, ATF-3 mediated, repression of Id-1 (27) contains an evolutionarily conserved overlapping putative HIF-1 binding motif as determined by a computer-generated algorithm. Therefore we hypothesized that ATF-3 generation in hypoxic cells interferes with HIF-1 transactivation of the Id-1 promoter; this antagonism of HIF-1 and ATF-3 is not expected to occur in hypoxic neuroblastoma cells where ATF-3 is not up-regulated. We used the region of the Id-1 promoter that contains the HIF-1/ATF binding sites as a probe to perform EMSAs on hypoxic neuroblastoma cells, which induce Id-1 but not ATF-3 (Fig. 3A), and hypoxic MEF and HaCAT cells, which induce ATF-3 and repress Id-1 expression (Fig. 3E).

In hypoxic SK-N-BE(2) cells a complex formed that could be selectively shifted with a HIF-1{alpha} antibody (Fig. 4C, lanes 2 and 9). A similar complex was seen in another hypoxic neuroblastoma line, SH-SY5Y (data not shown). Wild-type oligonucleotide competed for the hypoxia increased HIF-1 complex (lanes 3 and 4), although full competition required 30-fold cold oligonucleotide (data not shown). Intriguingly, an oligonucleotide mutated at the ATF site competed more effectively for this HIF-1 complex than wild-type oligonucleotide (lanes 5 and 6 versus lanes 3 and 4). In addition, when this ATF-mutated oligonucleotide was used as a probe it bound HIF-1 as well or better than wild-type oligonucleotide (lanes 7 and 8 versus lanes 1 and 2). These data suggest that HIF-1 directly binds to the Id-1 promoter and this binding is increased in the absence of ATF binding.

This HIF-1 complex was not noted in MEF and HaCAT cells, despite equivalent induction of HIF-1{alpha} protein expression (data not shown). In MEF and HaCAT cells we noted a less intense, slower migrating hypoxia-induced complex that competed with wild-type oligonucleotide (lanes 15 and 16) but not with an oligonucleotide with the ATF-3 site mutated (lanes 17 and 18). This slower migrating complex was not present in the neuroblastoma cells. In contrast with the HIF-1 complex, this complex did not form when the mutated ATF-3 oligonucleotide was used as a probe (lanes 19 and 20). This complex was also induced in cells treated with TGFbeta (data not shown) consistent with data that TGFbeta represses Id-1 transactivation through this motif in HaCAT cells (27). Although these results suggest that this complex is ATF-3, commercially available antibodies did not result in disruption of this complex, and this complex was not competed with wild-type ATF consensus oligonucleotide (data not shown). Therefore the polypeptides in this complex remain to be identified. Together these data suggest that HIF-1 only binds the Id-1 promoter in the absence of ATF-3, and ATF-3 antagonizes HIF-1 binding to the Id-1 promoter.


Figure 4
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 4.
Id-1 is a HIF-1 target in hypoxic neuroblastoma cells. A, shRNA to HIF-1a or a scrambled sequence was delivered into SK-N-BE(2) by a lentiviral expression vector. Cells were then rendered hypoxic for 8 h, and the induction of HIF-1a, Id-1, and VEGF were assessed by immunoblot. Coomassie Blue (coom.) serves as a loading control. Induction of Id-1 in hypoxic cells from two independent experiments was quantitated by densitometry of immunoblots and displayed graphically as the mean ± S.E. B, RNA from hypoxic and normoxic SK-N-BE(2) cells expressing a scrambled sequence or HIF-1a shRNA was isolated, and real-time PCR for lactate dehydrogenase, enolase, and Id-1 was performed. C, EMSA using nuclear extract (NE) from SK-N-BE(2), HaCAT, and MEF cells and labeled wild-type oligonucleotides from the portion of the Id-1 promoter demonstrated to bind ATF-3 (27) or a mutant derivative with the ATF site mutated as described under "Experimental Procedures."

 


Figure 5
View larger version (27K):
[in this window]
[in a new window]

  		FIGURE 5.
ATF-3 expression in hypoxic neuroblastoma cells regulates differentiation. SK-N-BE(2) cells transduced with empty vector (SK-N-BE(2)-plpc) or an ATF-3 expression vector (SK-N-BE(2)–ATF-3) were rendered hypoxic for 16 h, and RNA was collected. After reverse transcription, transcripts (18S, vimentin, Id-1, neuronal-specific enolase (nse), neurofilament light chain (nfl), neuropeptide y (npy), Sox9, and gap43) were determined by real-time PCR and normalized to 18 S RNA (18S), which was not altered in hypoxic cells. Reactions were performed in triplicate, with two to four biological replicates. Results are depicted as means ± S.E.

 
ATF-3 Regulates Differentiation of Hypoxic Neuroblastoma Cells—Previous studies have demonstrated that long term, moderately hypoxic neuroblastoma cells (which would be predicted to have an activated UPR) down-regulate several ganglionic/neuronal genes (38). This has led to the proposal that hypoxia pushes neuroblastoma cells toward a more immature phenotype, resembling neural crest-derived neuronal precursor cells (13). Because down-regulation of Id family members is associated with neuroblastoma differentiation, we sought to determine whether previously described hypoxic responses were related to hypoxic up-regulation of Id-1 (and therefore the absence of the UPR in these cells).

As discussed previously, we found that the introduction of ATF-3 in hypoxic neuroblastoma cells blocks up-regulation of Id-1 (Fig. 3E). SK-N-BE(2)-plpc control cells (which induce Id-1 when hypoxic) and SK-N-BE(2)-ATF-3 expressing cells (which do not induce Id-1 when hypoxic) were rendered hypoxic for 16 h, and the expression of markers of differentiation was assessed by quantitative RT-PCR. As reported previously, several neuronal differentiation markers were diminished in hypoxic SK-N-BE(2)-plpc cells, including neurofilament light chains (nfl) neuropeptide Y (npy), and gap43 (13, 38) (Fig. 5). Rendering SK-N-BE(2)-plpc cells hypoxic also resulted in an increase in Sox9, which is noted to be highly expressed in neural crest stem cells (39). While neuronal specific enolase (nse) mRNA, typically a marker of differentiation, was up-regulated in hypoxic SK-N-BE(2) cells, this may be a reflection of HIF-1 mediated activation of the nse promoter and may not reflect differentiation status.

As predicted from protein expression data (Fig. 3E), the presence of ATF-3 repressed Id-1 mRNA up-regulation in hypoxic SK-N-BE(2)-ATF-3 cells (Fig. 5). In contrast to hypoxic SK-N-BE(2)-plpc cells, the loss of the neuronal markers nfl and npy and induction of Sox9 were not seen in hypoxic SK-N-BE(2)-ATF-3 cells. Of note, the increase of nse in parental hypoxic cells was also blocked by the expression of ATF-3. While the nse promoter has conserved ATF and HIF-1 binding motifs, whether ATF-3 directly blocks HIF-1 transactivation of nse is unknown at this time. Interesting the down-regulation of gap43 seen in hypoxic SK-N-BE(2)-plpc cells was even more pronounced in SK-N-BE(2)-ATF-3 cells; regulation of gap43 is primarily due to Nex1, a member of the NeuroD family (40). Inhibition of Nex1 by hypoxic-generated Id-1 would explain our observations, and this too deserves further study. Together, our data suggest that hypoxic regulation of Id-1 promote the loss of some neuronal markers in neuroblastoma, as well as the acquisition of at least one stem cell marker. However, the full effect of hypoxia on neuroblastoma differentiation is likely to differ with duration and severity of hypoxic incubation and is undoubtably complicated by hypoxic activation of the other pathways including notch and AKT (41, 42).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
We have established that Id-1 is highly regulated in hypoxic cells primarily at the transcriptional level. Our data demonstrate that in most cells Id-1 is down-regulated by hypoxia-induced ATF-3. Hypoxic repression of Id-1 (and perhaps other Id family members) would be predicted to promote cellular growth arrest. This may be a normal, physiological response by which hypoxic cells diminish energy needs. The Id proteins also play a crucial role in development. Bone marrow and lymph nodes are relatively hypoxic, and the role of HIF-1 in embryogenesis suggests physiological hypoxia occurs during embryogenesis (11, 43, 44). In the absence of hypoxia-induced ATF-3, Id-1 is up-regulated by HIF-1. One mechanism by which differentiation is blocked in some hypoxic cells (such as hematopoietic stem cells) and induced in others may be the hypoxic induction or repression, respectively, of Id family members.

In agreement with other recent findings we have found that in hypoxic cells PERK phosphorylates eIF2{alpha} leading to the induction of ATF-4 and ATF-4 targets including CHOP. eIF2{alpha} phosphorylation is also, in part, responsible for hypoxic up-regulation of ATF-3 and repression of Id-1. Remarkably, we have noted that the UPR is markedly diminished in hypoxic neuroblastoma cells. Functional ATF-4 and PERK are necessary for ras-transformed MEFs to grow as tumors in nude mice, and ATF-4 up-regulation has been noted histochemically in hypoxic human cervical cancer (32). However, the functional status of the UPR in other human cancers, many of which have mutations that allow them to tolerate cellular stresses, has not been well surveyed. In some cancers, such as neuroblastoma, the absence of a functional UPR may actually be beneficial to tumorigenesis. For example, the absence of the UPR in neuroblastoma cells also results in a failure of CHOP induction, a transcriptional target of ATF-4 and a reported pro-apoptotic protein (45).

The high basal phosphorylation of eIF2{alpha} we observed in neuroblastoma cells may be due to diminished expression of gadd34, an ATF-4 target that de-phosphorylates eIF2{alpha} and thus serves as a feedback loop (46). The significance of high basal eIF2{alpha} phosphorylation in neuroblastoma cells is unknown, but this observation may provide a clue to the aberrant hypoxic response in these cells. eIF2{alpha} phosphorylation normally results in the binding and inactivation of eIF2B, a GTP exchange factor necessary for eIF2 function and subsequent protein translation (47). Mutations in the regulatory subunits of the eIF2B complex, which have been generated experimentally and are also present in patients with various leukodystrophies, lead to decreased activity of eIF2B and render eIF2B resistant to inhibition by phosphorylated eIF2{alpha}, although many of these mutations appear to actually increase the stress response of these cells (48). It will be interesting to determine whether neuroblastoma cells have mutations in members of the eIF2B complex that render this complex immune to inhibition by phosphorylated eIF2{alpha}.


Figure 6
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 6.
Model of Id-1 regulation in hypoxic non-neuroblastoma cells (A) and neuroblastoma cells (B).

 
The identification of ATF-3 as a hypoxia-generated transcriptional repressor may provide insight into the mechanism of gene repression in hypoxic cells. Because Id-1 is up-regulated by HIF-1 and down-regulated by ATF-3, our findings demonstrate that ATF-3 can modulate HIF-1 activity. In addition, since ATF-3 is not induced in some hypoxic cells, our data demonstrate cell specific modulation of HIF-1 activity. While we noted up-regulation of Id-1 in hypoxic ATF-3–/– MEFs, the degree of induction (1.6-fold, Fig. 1D) was more modest than the induction of Id-1 in neuroblastoma cells (3.3-fold, Fig. 5) suggesting that other features may also contribute to the HIF-1 mediated up-regulation of Id-1 in hypoxic neuroblastoma cells. It is tempting to hypothesize that the antagonism of ATF-3 and HIF-1 may play a role in modulating expression of genes in addition to Id-1, and this may help explain some of the tissue and cell type differences in hypoxic response (Fig. 6).

HIF-1a is stabilized in hypoxic tumors and by oncogenic alterations often found in cancer and is an indicator of poor prognosis (reviewed in Ref. 1). HIF-1 transactivates glucose transporters, glycolytic enzymes, angiogenic factors, and other genes important for hypoxic adaptation to the tumor microenvironment (reviewed in Ref. 1). Whether Id proteins are HIF-1 targets in hypoxic tumors other than neuroblastoma is unknown. Id proteins plays a vital role in proliferation, endothelial cell recruitment, and neo-vascularization in animal models, and Id-1 is a transcriptional repressor of thrombospondin, a negative regulator of angiogenesis (17, 18). Further studies are needed to determine both the phenotypic results of Id-1 down-regulation in hypoxic cells and whether the establishment of ATF-3, or the UPR, in hypoxic neuroblastoma cells can affect proliferation, angiogenesis, or differentiation in vivo through manipulation of Id-1.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grant CA89265 and by a New York University Whitehead Fellowship (to L. B. G.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Division of Hematology, Dept. of Medicine, New York University School of Medicine, Tisch 401, 550 1st Ave., New York, NY 10016. Tel.: 212-263-8038; Fax: 212-263-8444; E-mail: lawrence.gardner{at}med.nyu.edu.

2 The abbreviations used are: HLH, helix-loop-helix; MEF, mouse embryo fibroblast; DMEM, Dulbecco's modified Eagle's medium; RT, reverse transcription; shRNA, short hairpin RNA; EMSA, electromobility shift assay; TGF, transforming growth factor; UPR, unfolded protein response; eiF2, eukaryotic initiation factor 2; ER, endoplasmic reticulum; VEGF, vascular endothelial growth factor. Back

3 L. B. Gardner, unpublished data. Back


   ACKNOWLEDGMENTS
 
We thank H. P. Harding and D. Ron for their kind gift of many useful reagents including the PERK and ATF4 knock-out MEFs, T. Hai for ATF-3 knock-out MEFs, and R. Kaufman for the eIF2{alpha} S51A MEFs. We thank Francesc Ventura and Yibin Kang for supplying the Id-1 promoter/luciferase constructs. We also thank R. Alani, G. Kato, and M. Pagano and his laboratory, B. Dynlacht and his laboratory, and E. Skolnik for reagents. These experiments were initiated in the laboratory of Chi Dang, with his support and guidance and the assistance of Irina Chernysheva. We gratefully acknowledge Heather Harding, Jeffrey Z. S. Ye, and Gregory David for their many useful discussions. Heather Harding, Gregory David, Brian Dynlacht, Linda Lee, Simon Karpatkin, David Ron, and Ed Skolnik provided helpful criticisms in the preparation of this manuscript.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Semenza, G. L. (2003) Nat. Rev. Cancer 3, 721–732[CrossRef][Medline] [Order article via Infotrieve]
  2. Kitamuro, T., Takahashi, K., Ogawa, K., Udono-Fujimori, R., Takeda, K., Furuyama, K., Nakayama, M., Sun, J., Fujita, H., Hida, W., Hattori, T., Shirato, K., Igarashi, K., and Shibahara, S. (2003) J. Biol. Chem. 278, 9125–9133[Abstract/Free Full Text]
  3. Denko, N. C., Fontana, L. A., Hudson, K. M., Sutphin, P. D., Raychaudhuri, S., Altman, R., and Giaccia, A. J. (2003) Oncogene 22, 5907–5914[CrossRef][Medline] [Order article via Infotrieve]
  4. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B., and Simon, M. C. (2003) Mol. Cell. Biol. 23, 9361–9374[Abstract/Free Full Text]
  5. Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., and Maity, A. (2001) J. Biol. Chem. 276, 9519–9525[Abstract/Free Full Text]
  6. Mazure, N. M., Chen, E. Y., Yeh, P., Laderoute, K. R., and Giaccia, A. J. (1996) Cancer Res. 56, 3436–3440[Abstract/Free Full Text]
  7. Gardner, L. B., Li, Q., Park, M. S., Flanagan, W. M., Semenza, G. L., and Dang, C. V. (2001) J. Biol. Chem. 276, 7919–7926[Abstract/Free Full Text]
  8. Gardner, L. B., Li, F., Yang, X., and Dang, C. V. (2003) Mol. Cell. Biol. 23, 9032–9045[Abstract/Free Full Text]
  9. Ramirez-Bergeron, D. L., Runge, A., Dahl, K. D., Fehling, H. J., Keller, G., and Simon, M. C. (2004) Development (Camb.) 131, 4623–4634[Abstract/Free Full Text]
  10. Manotham, K., Tanaka, T., Matsumoto, M., Ohse, T., Inagi, R., Miyata, T., Kurokawa, K., Fujita, T., Ingelfinger, J. R., and Nangaku, M. (2004) Kidney Int. 65, 871–880[CrossRef][Medline] [Order article via Infotrieve]
  11. Danet, G. H., Pan, Y., Luongo, J. L., Bonnet, D. A., and Simon, M. C. (2003) J. Clin. Invest. 112, 126–135[CrossRef][Medline] [Order article via Infotrieve]
  12. Yun, Z., Maecker, H. L., Johnson, R. S., and Giaccia, A. J. (2002) Dev. Cell 2, 331–341[CrossRef][Medline] [Order article via Infotrieve]
  13. Axelson, H., Fredlund, E., Ovenberger, M., Landberg, G., and Pahlman, S. (2005) Semin. Cell Dev. Biol. 16, 554–563[CrossRef][Medline] [Order article via Infotrieve]
  14. Ruzinova, M. B., and Benezra, R. (2003) Trends Cell Biol. 13, 410–418[CrossRef][Medline] [Order article via Infotrieve]
  15. Alani, R. M., Young, A. Z., and Shifflett, C. B. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7812–7816[Abstract/Free Full Text]
  16. Lasorella, A., Noseda, M., Beyna, M., Yokota, Y., and Iavarone, A. (2000) Nature 407, 592–598[CrossRef][Medline] [Order article via Infotrieve]
  17. Volpert, O. V., Pili, R., Sikder, H. A., Nelius, T., Zaichuk, T., Morris, C., Shiflett, C. B., Devlin, M. K., Conant, K., and Alani, R. M. (2002) Cancer Cell 2, 473–483[CrossRef][Medline] [Order article via Infotrieve]
  18. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., Wu, Y., Hicklin, D., Zhu, Z., Hackett, N. R., Crystal, R. G., Moore, M. A., Hajjar, K. A., Manova, K., Benezra, R., and Rafii, S. (2001) Nat. Med. 7, 1194–1201[CrossRef][Medline] [Order article via Infotrieve]
  19. Jogi, A., Persson, P., Grynfeld, A., Pahlman, S., and Axelson, H. (2002) J. Biol. Chem. 277, 9118–9126[Abstract/Free Full Text]
  20. Lasorella, A., Boldrini, R., Dominici, C., Donfrancesco, A., Yokota, Y., Inserra, A., and Iavarone, A. (2002) Cancer Res. 62, 301–306[Abstract/Free Full Text]
  21. Hartman, M. G., Lu, D., Kim, M. L., Kociba, G. J., Shukri, T., Buteau, J., Wang, X., Frankel, W. L., Guttridge, D., Prentki, M., Grey, S. T., Ron, D., and Hai, T. (2004) Mol. Cell. Biol. 24, 5721–5732[Abstract/Free Full Text]
  22. Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calfon, M., Sadri, N., Yun, C., Popko, B., Paules, R., Stojdl, D. F., Bell, J. C., Hettmann, T., Leiden, J. M., and Ron, D. (2003) Mol. Cell 11, 619–633[CrossRef][Medline] [Order article via Infotrieve]
  23. Jiang, H. Y., Wek, S. A., McGrath, B. C., Lu, D., Hai, T., Harding, H. P., Wang, X., Ron, D., Cavener, D. R., and Wek, R. C. (2004) Mol. Cell. Biol. 24, 1365–1377[Abstract/Free Full Text]
  24. Scheuner, D., Song, B., McEwen, E., Liu, C., Laybutt, R., Gillespie, P., Saunders, T., Bonner-Weir, S., and Kaufman, R. J. (2001) Mol. Cell 7, 1165–1176[CrossRef][Medline] [Order article via Infotrieve]
  25. Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., and Dewhirst, M. W. (2005) Cancer Cell 8, 99–110[CrossRef][Medline] [Order article via Infotrieve]
  26. Lopez-Rovira, T., Chalaux, E., Massague, J., Rosa, J. L., and Ventura, F. (2002) J. Biol. Chem. 277, 3176–3185[Abstract/Free Full Text]
  27. Kang, Y., Chen, C. R., and Massague, J. (2003) Mol. Cell 11, 915–926[CrossRef][Medline] [Order article via Infotrieve]
  28. Trausch-Azar, J. S., Lingbeck, J., Ciechanover, A., and Schwartz, A. L. (2004) J. Biol. Chem. 279, 32614–32619[Abstract/Free Full Text]
  29. Hai, T., Wolfgang, C. D., Marsee, D. K., Allen, A. E., and Sivaprasad, U. (1999) Gene Expr. 7, 321–335[Medline] [Order article via Infotrieve]
  30. Harding, H. P., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M., and Ron, D. (2000) Mol. Cell 6, 1099–1108[CrossRef][Medline] [Order article via Infotrieve]
  31. Blais, J. D., Filipenko, V., Bi, M., Harding, H. P., Ron, D., Koumenis, C., Wouters, B. G., and Bell, J. C. (2004) Mol. Cell. Biol. 24, 7469–7482[Abstract/Free Full Text]
  32. Bi, M., Naczki, C., Koritzinsky, M., Fels, D., Blais, J., Hu, N., Harding, H., Novoa, I., Varia, M., Raleigh, J., Scheuner, D., Kaufman, R. J., Bell, J., Ron, D., Wouters, B. G., and Koumenis, C. (2005) EMBO J. 24, 3470–3481[CrossRef][Medline] [Order article via Infotrieve]
  33. Koumenis, C., Naczki, C., Koritzinsky, M., Rastani, S., Diehl, A., Sonenberg, N., Koromilas, A., and Wouters, B. G. (2002) Mol. Cell. Biol. 22, 7405–7416[Abstract/Free Full Text]
  34. Koritzinsky, M., Magagnin, M. G., van den Beucken, T., Seigneuric, R., Savelkouls, K., Dostie, J., Pyronnet, S., Kaufman, R. J., Weppler, S. A., Voncken, J. W., Lambin, P., Koumenis, C., Sonenberg, N., and Wouters, B. G. (2006) EMBO J. 25, 1114–1125[CrossRef][Medline] [Order article via Infotrieve]
  35. Hashimoto, Y., Zhang, C., Kawauchi, J., Imoto, I., Adachi, M. T., Inazawa, J., Amagasa, T., Hai, T., and Kitajima, S. (2002) Nucleic Acids Res. 30, 2398–2406[Abstract/Free Full Text]
  36. Calfon, M., Zeng, H., Urano, F., Till, J. H., Hubbard, S. R., Harding, H. P., Clark, S. G., and Ron, D. (2002) Nature 415, 92–96[CrossRef][Medline] [Order article via Infotrieve]
  37. Lofstedt, T., Jogi, A., Sigvardsson, M., Gradin, K., Poellinger, L., Pahlman, S., and Axelson, H. (2004) J. Biol. Chem. 279, 39223–39231[Abstract/Free Full Text]
  38. Jogi, A., Ora, I., Nilsson, H., Lindeheim, A., Makino, Y., Poellinger, L., Axelson, H., and Pahlman, S. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7021–7026[Abstract/Free Full Text]
  39. Cheung, M., and Briscoe, J. (2003) Development (Camb.) 130, 5681–5693[Abstract/Free Full Text]
  40. Uittenbogaard, M., Martinka, D. L., and Chiaramello, A. (2003) J. Neurochem. 84, 678–688[CrossRef][Medline] [Order article via Infotrieve]
  41. Lopez-Carballo, G., Moreno, L., Masia, S., Perez, P., and Barettino, D. (2002) J. Biol. Chem. 277, 25297–25304[Abstract/Free Full Text]
  42. Pahlman, S., Stockhausen, M. T., Fredlund, E., and Axelson, H. (2004) Semin. Cancer Biol. 14, 365–373[CrossRef][Medline] [Order article via Infotrieve]
  43. Covello, K. L., and Simon, M. C. (2004) Curr. Top. Dev. Biol. 62, 37–54[Medline] [Order article via Infotrieve]
  44. Caldwell, C. C., Kojima, H., Lukashev, D., Armstrong, J., Farber, M., Apasov, S. G., and Sitkovsky, M. V. (2001) J. Immunol. 167, 6140–6149[Abstract/Free Full Text]
  45. Marciniak, S. J., Yun, C. Y., Oyadomari, S., Novoa, I., Zhang, Y., Jungreis, R., Nagata, K., Harding, H. P., and Ron, D. (2004) Genes Dev. 18, 3066–3077[Abstract/Free Full Text]
  46. Novoa, I., Zeng, H., Harding, H. P., and Ron, D. (2001) J. Cell Biol. 153, 1011–1022[Abstract/Free Full Text]
  47. Sudhakar, A., Ramachandran, A., Ghosh, S., Hasnain, S. E., Kaufman, R. J., and Ramaiah, K. V. (2000) Biochemistry 39, 12929–12938[CrossRef][Medline] [Order article via Infotrieve]
  48. Kantor, L., Harding, H. P., Ron, D., Schiffmann, R., Kaneski, C. R., Kimball, S. R., and Elroy-Stein, O. (2005) Hum. Genet, 1–8

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
Y. Kashiwakura, K. Ochiai, M. Watanabe, F. Abarzua, M. Sakaguchi, M. Takaoka, R. Tanimoto, Y. Nasu, N.-h. Huh, and H. Kumon
Down-regulation of Inhibition of Differentiation-1 via Activation of Activating Transcription Factor 3 and Smad Regulates REIC/Dickkopf-3-Induced Apoptosis
Cancer Res., October 15, 2008; 68(20): 8333 - 8341.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Qian and X. Chen
ID1, Inhibitor of Differentiation/DNA Binding, Is an Effector of the p53-dependent DNA Damage Response Pathway
J. Biol. Chem., August 15, 2008; 283(33): 22410 - 22416.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
L. B. Gardner
Hypoxic Inhibition of Nonsense-Mediated RNA Decay Regulates Gene Expression and the Integrated Stress Response
Mol. Cell. Biol., June 1, 2008; 28(11): 3729 - 3741.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/1/240    most recent
M607275200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nemetski, S. M.
Right arrow Articles by Gardner, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nemetski, S. M.
Right arrow Articles by Gardner, L. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement